Are there medical conditions or medications that increase or decrease female ejaculation?

1. Sexual function is multifactorial — start by defining the problem

Sexual response and orgasm — and by extension female ejaculation or “squirting” — are physiological events influenced by hormones, neural reflexes, psychological state, partner dynamics and medication effects; major sexual-medicine reviews treat orgasmic disorders separately from male premature ejaculation and warn clinicians to rule out medical causes or drug effects before assigning a primary sexual-dysfunction diagnosis ^{[1] [5]}.

2. Antidepressants (SSRIs) blunt orgasm and can reduce ejaculatory phenomena

Multiple clinical reviews and treatment guides state that selective serotonin reuptake inhibitors (SSRIs) commonly delay or impair orgasm in both sexes and have been repurposed precisely because they delay ejaculation in men — the same serotonergic mechanism can reduce orgasm intensity or timing in women and therefore may reduce the occurrence or volume of female ejaculation ^{[1] [2]}. Population-level counseling resources and sexual-health organizations likewise list antidepressants among the drugs most often implicated in sexual side effects for women ^[6].

3. Other drug classes: stimulants, antihypertensives, GLP‑1s and more — varied effects reported

Older and contemporary drug‑side‑effect surveys and clinical reviews flag many medication classes as affecting sexual function: stimulants and some ADHD drugs can alter arousal and ejaculation timing via sympathetic activation, β‑blockers and diuretics have long been associated with reduced libido/sexual response, and recent clinical commentary raises the possibility that GLP‑1 receptor agonists (semaglutide, liraglutide) may indirectly affect sexual function — though specific, high‑quality data linking these newer agents to changes in female ejaculation are not detailed in the sources provided ^{[4] [7]}. Available sources do not mention definitive, controlled studies directly measuring female ejaculation changes with these drugs.

4. Local/topical anesthetics and partner effects — an indirect pathway

Sex-medicine reviews of premature ejaculation treatments note that topical anesthetics (used on male genitalia) can reduce penile sensitivity and, when transferred to the partner via intercourse, cause vaginal numbness and female anorgasmia — an indirect route by which a partner’s medication can reduce female orgasmic response and likely reduce or prevent female ejaculation during intercourse ^{[2] [8]}.

5. Hormones and medical conditions — plausible biologic links, limited direct evidence

Reviews of sexual dysfunction emphasize roles for sex hormones and endocrine factors in orgasm and ejaculatory processes; for men, testosterone influences ejaculatory timing, and guideline overviews stress assessing hormonal and medical contributors to sexual complaints ^{[9] [10]}. However, among the sources provided, robust, direct evidence specifically tying discrete female medical conditions (e.g., endocrine disorders) to increased or decreased female ejaculation is not presented; available sources do not mention controlled studies that quantify such links for female ejaculation specifically ^{[9] [3]}.

6. Epidemiology and definitional challenges — why the evidence is mixed

Female ejaculation and “squirting” are variably defined across studies and clinical reviews; historical and recent reviews note broad interindividual variability and longstanding debate about sources of fluid, which complicates measurement and comparison across studies — this definitional heterogeneity helps explain why medication‑effect data are inconsistent or sparse ^{[3] [11]}.

7. Clinical implications — what clinicians and patients should do

Guideline-oriented sexual-medicine sources recommend a comprehensive assessment of sexual complaints that includes medications, medical comorbidities and partner factors; when a patient reports changes in orgasm or ejaculation, clinicians should review prescriptions (antidepressants are high‑priority suspects), consider dose changes or alternate agents, and include psychosexual counseling or behavioral strategies where appropriate ^{[1] [2]}.

8. Limits of current reporting and research gaps

The sources show substantial literature on drug‑induced sexual dysfunction generally and on male ejaculation disorders specifically, but they contain limited high‑quality, female‑specific studies measuring medication or disease effects on female ejaculation volume, frequency or physiology; available sources do not provide definitive controlled trials that isolate causes for increased female ejaculation ^{[11] [3]}.

Sources cited in this briefing: see clinical and review articles summarized above — antidepressant-related sexual side effects and SSRI use in treating/delaying ejaculation ^{[1] [2]}, general medication lists and sexual side‑effect summaries ^{[4] [6]}, topical anesthetic partner‑effect warnings ^{[2] [8]}, definitional and descriptive reviews of female ejaculation ^{[3] [11]}, and guideline overviews recommending comprehensive evaluation ^{[10] [1]}.